Protocol for the Examination of Specimens from Patients with Tumors of the Peritoneum

Protocol applies to all primary borderline and malignant epithelial tumors and malignant mesothelial neoplasms of the peritoneum.

No AJCC/UICC TNM Staging System
Protocol web posting date: October 2009

Procedure
- Resection

Authors
Katja Gwin, MD, PhD, FCAP
Department of Pathology, University of Chicago, Chicago, Illinois
Philip A. Branton, MD, FCAP
Department of Pathology, Inova Fairfax Hospital, Fairfax, Virginia
Marisa R. Nucci, MD, FCAP
Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts
Esther Oliva, MD, FCAP
Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts
Kumarasen Cooper, MD, FCAP
Department of Pathology, University of Vermont, Burlington, Vermont
For the Members of the Cancer Committee, College of American Pathologists

Previous lead contributors: Karen Antman, MD; Robert E. Scully, MD
© 2009 College of American Pathologists (CAP). All rights reserved.

The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College.

The CAP also authorizes physicians and other health care practitioners to make modified versions of the Protocols solely for their individual use in reporting on surgical specimens for individual patients, teaching, and carrying out medical research for non-profit purposes.

The CAP further authorizes the following uses by physicians and other health care practitioners, in reporting on surgical specimens for individual patients, in teaching, and in carrying out medical research for non-profit purposes: (1) **Dictation** from the original or modified protocols for the purposes of creating a text-based patient record on paper, or in a word processing document; (2) **Copying** from the original or modified protocols into a text-based patient record on paper, or in a word processing document; (3) The use of a **computerized system** for items (1) and (2), provided that the Protocol data is stored intact as a single text-based document, and is not stored as multiple discrete data fields.

Other than uses (1), (2), and (3) above, the CAP does not authorize any use of the Protocols in electronic medical records systems, pathology informatics systems, cancer registry computer systems, computerized databases, mappings between coding works, or any computerized system without a written license from CAP. Applications for such a license should be addressed to the SNOMED Terminology Solutions division of the CAP.

Any public dissemination of the original or modified Protocols is prohibited without a written license from the CAP.

The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the “Surgical Pathology Cancer Case Summary (Checklist)” portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.

The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the checklist elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with these documents. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.

The inclusion of a product name or service in a CAP publication should not be construed as an endorsement of such product or service, nor is failure to include the name of a product or service to be construed as disapproval.
CAP Peritoneum Protocol Revision History

Version Code
The definition of the version code can be found at www.cap.org/cancerprotocols.

Version: Peritoneum 3.0.0.0

Summary of Changes
No changes have been made since the October 2009 release.
Surgical Pathology Cancer Case Summary (Checklist)

Protocol web posting date: October 2009

PERITONEUM: Resection

Select a single response unless otherwise indicated.

Specimen (select all that apply)
___ Peritoneum
___ Omentum
___ Bilateral ovaries
___ Bilateral fallopian tubes
___ Uterus
___ Other (specify): _______________________
___ Not specified

Procedure
___ Peritoneal resection
___ Omentectomy
___ Hysterectomy with bilateral salpingo-oophorectomy
___ Other (specify): _______________________
___ Not specified

Lymph Node Sampling
___ No lymph node sampling
___ Obturator lymph nodes
___ Common iliac lymph nodes
___ Periaortic lymph nodes
___ Inguinal lymph nodes
___ Pelvic lymph nodes not otherwise specified (NOS)
___ Retroperitoneal lymph nodes NOS
___ Other lymph nodes (specify): _______________________

Tumor Site
Specify: ______________________________
___ Cannot be determined

Tumor Size (Peritoneum / Omentum)
Greatest dimension: ___ cm
*Additional dimensions: ___ x ___ cm
___ Cannot be determined (see Comment)

Tumor Focality
___ Unifocal
___ Multifocal
___ Cannot be determined

* Data elements with asterisks are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.
**Size of Other Locations**

**Left Ovary**
- No tumor
- Confined to surface epithelium
- Surface and cortical stroma involvement
- Only ovarian substance involvement
- Greatest dimensions: ___ x ___ cm
  *Additional dimension: ___ cm
- Cannot be determined (see Comment)

**Right Ovary**
- No tumor
- Confined to surface epithelium
- Surface and cortical stroma involvement
- Only ovarian substance involvement
- Greatest dimensions: ___ x ___ cm
  *Additional dimension: ___ cm
- Cannot be determined (see Comment)

**Other (specify):______________________**
Greatest dimension: ___ cm
*Additional dimensions:___ x ___ cm
- Cannot be determined (see Comment)

**Histologic Type (Note A, Note B)**
- Malignant mesothelioma, epithelioid
- Malignant mesothelioma, sarcomatoid (spindle cell)
- Malignant mesothelioma, biphasic
- Malignant mesothelioma, other (specify):_________________________
- Serous borderline tumor (of low malignant potential)
- Serous carcinoma
- Other malignant tumor of Mullerian type (specify):_________________
- Other (specify):_________________________
- Malignant tumor, type cannot be determined

**Histologic Grade (Note C)**
- Not applicable (borderline neoplasms and mesotheliomas)
- GX: Cannot be assessed
- G1: Well differentiated
- G2: Moderately differentiated
- G3: Poorly differentiated
- Other (specify):_________________________

**Lymph-Vascular Invasion**
- Not identified
- Present
- Indeterminate

* Data elements with asterisks are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.
**Effusions**
*___ Positive ascites/peritoneal washings
*___ Positive pleural effusions
*___ Indeterminate

**Metastasis**
*___ None identified
*___ Microscopic peritoneal metastasis beyond pelvis (no macroscopic tumor)
*___ Macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension
*___ Peritoneal metastasis beyond pelvis more than 2 cm in greatest dimension and/or regional lymph node metastasis
*___ Liver capsule metastasis
*___ Liver parenchymal metastasis
*___ Other (specify): ______________________________________
*___ Cannot be determined

**Additional Pathologic Findings (select all that apply)**
*___ None identified
*___ Ferruginous bodies
*___ Endosalpingiosis
*___ Endometriosis
*___ Mesothelial inclusion cysts
*___ Other (specify): ______________________________________

**Ancillary Studies**
* Specify: ______________________________

**Clinical History**
* Specify: ______________________________
*___ Not specified

**Comment(s)**

---
* Data elements with asterisks are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.
Explanatory Notes

A. Histologic Type
This protocol refers only to primary borderline and malignant epithelial tumors of the peritoneum. Secondary tumors, for example, those causing pseudomyxoma peritonei (almost always of appendiceal origin), are not addressed. However, in some cases "peritoneal spread" of a serous borderline tumor may actually reflect a primary peritoneal tumor rather than a metastasis from the ovary.

Classification of Peritoneal Tumors
Benign
- Adenomatoid tumor
- Benign multicystic mesothelioma (multilocular peritoneal inclusion cyst)
- Mesothelial cyst(s) (unilocular) (free or attached)
- Well-differentiated papillary mesothelioma
- Solitary fibrous tumor (fibrous mesothelioma) (usually benign)

Malignant
- Diffuse malignant mesothelioma
  - Epithelioid type
  - Sarcomatoid type
  - Biphasic type
  - Rare types
- Serous tumor of borderline malignancy (of low malignant potential)
- Serous carcinoma
- Malignant tumors of other Mullerian types
- Sarcomas

# Rare types include desmoplastic, small cell, lymphohistiocytoid, decidual, and undifferentiated types.

## When this tumor involves the extraovarian peritoneum significantly and the ovarian surface minimally or not at all, it is generally considered to be of peritoneal origin.

### The Gynecological Oncology Group has adopted the following criteria for the diagnosis of primary peritoneal serous carcinoma:
1. Both ovaries are either normal in size or enlarged by a benign process. In the judgment of the surgeon and the pathologist, the bulk of the tumor involves the peritoneum, and the extent of tumor involvement at 1 or more extraovarian sites is greater than that on the surface of or within either ovary.
2. Microscopic examination of the ovaries reveals: (a) no tumor; (b) tumor confined to the surface epithelium, with no evidence of cortical invasion; (c) tumor involving the ovarian surface and the underlying cortical stroma, but less than 5 x 5 mm in diameter; or (d) tumor less than 5 x 5 mm within the ovarian substance, with or without surface involvement.
3. The histologic and cytologic characteristics of the tumor are predominantly serous and similar or identical to those of ovarian serous papillary carcinoma of any grade.
4. If an oophorectomy has been performed in the past, a confident diagnosis of primary peritoneal serous carcinoma requires 1 of the following: (a) a pathology report to
document the absence of carcinoma in the ovarian specimen, with review of all the slides if the oophorectomy has been performed within 5 years of the current procedure; (b) if the oophorectomy has been performed more than 5 years before the current procedure, the pathology report of the specimen should be obtained, and the slides should be reviewed if still available. The peritoneal tumor should be interpreted in light of the ovarian findings.

B. Special Studies
Histochemical, immunohistochemical, and electron microscopic studies are helpful to routine microscopic evaluation in the diagnosis of mesothelioma. These tumors are usually mucicarmine and Pas-D negative. They may be positive for Alcian blue or colloidal iron stains. Mesotheliomas usually are positive for different keratins, including cytokeratins 5/6, EMA, thrombomodulin, WT1, D2-40 (podoplanin), and calretinin. They are usually negative for CEA, B72.3, BER-EP4, and CD15 (Leu-M1), although they may be positive for single antibodies. In all these cases, a panel of antibodies is recommended. (For further detail, see Thoracic Mesothelium protocol.)

C. Histologic Grade
There is no established grading system for malignant mesotheliomas. Serous and other Mullerian-type tumors can be graded according to the criteria used for similar tumors in the female genital tract, as shown below. (For further detail, see Ovary protocol.)

Grade X Cannot be assessed
Grade 1 Well differentiated
Grade 2 Moderately differentiated
Grade 3 Poorly differentiated (tumors with minimal differentiation seen in very small foci)

D. Staging of Peritoneal Tumors
There is no widely accepted staging system for peritoneal tumors, but their extent may have prognostic significance.9 Thus, it is important to determine whether a mesothelioma is unifocal, multifocal, or diffuse10, and whether there are lymph node or distant metastases. Peritoneal serous carcinomas are generally staged as though they were stage II to stage IV ovarian cancers. (For further detail, see ovary protocol.)

References


